

KYOWA HAKKO KIRIN - ARQ-197 Enters Japanese Ph III - Success Will Boost KHK's Onco Ambitions!

<https://marketpublishers.com/r/KE6101FC0AAEN.html>

Date: August 2011

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: KE6101FC0AAEN

Abstracts

Kyowa Hakko Kirin announced to initiate Ph III JP trial for ARQ-197 (Ph II, c-Met inhibitor, advance or metastatic NSCLC, oral). JP Ph III design will follow JP Ph II and international Ph II trails that compared overall survival (OS) of patients treated with ARQ 197 and Tarceva (erlotinib) vs. placebo and Tarceva. Data presented earlier at ASCO & ESMO suggest favorable outcome in Ph III. ARQ-197, if reaches market, will be targeting ~ 30,000 patients in Japan and expecting a generous 10% discounted launch price to Tarceva with an initial penetration on 10%, which will grow to ~50% by 2018 of total potential market.

This report analyzes NSCLC market, current therapy paradigm and opportunity for ARQ 197 in Japan.

Contents

COMPANIES MENTIONED

Kyowa Hakko Kirin, 4151

I would like to order

Product name: KYOWA HAKKO KIRIN - ARQ-197 Enters Japanese Ph III - Success Will Boost KHK's Onco Ambitions!

Product link: <https://marketpublishers.com/r/KE6101FC0AAEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/KE6101FC0AAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

